Table 1.
Effects of in vivo treatment of K+-depleted rats for 10 days with ACTZ, DCP or BFT on vacuole formation in TA muscle
| Muscle type and treatments | Number of fibres per muscle sample | Number of fibres per mm2 | Number of vacuoles | Number of vacuoles per 1000 fibres |
|---|---|---|---|---|
| TA of normokalemic rats (4) | 4330±300 | 72.4±7.1 | 28.5±6.5 | 8.7±3 |
| TA of K+-depleted rats (5) | 1516±309 | 27.5±2.4 | 39.0±12* | 24.7±3.4* |
| TA of K+-depleted rats treated with ACTZ (7) | 2743±469 | 208.6±38.3 | 18.1±4.3 | 7.2±1.4** |
| TA of K+-depleted rats treated with BFT (4) | 5011±349 | 137.3±17.0 | 181.7±36.2 | 36.7±7.3 |
| TA of K+-depleted rats treated with DCP (6) | 2221±199 | 175.3±17.5 | 199.7±77.9 | 83.1±24** |
Abbreviations: ACTZ, acetazolamide; BFT, bendroflumethiazide; DCP, dichlorphenamide; TA, tibialis anterioris.
All drugs were administered at a dose of 5.6 mg kg−1 day−1. The quantification of vacuoles and analysis were performed by counting the number of vacuoles per 1000 muscle fibres in high-resolution digital images of muscle samples. The numbers in the brackets represent the number of rats.
*
Significantly different from the data of normokalemic rats (P<0.05).
**
Significantly different from the data of untreated K+-depleted rats (P<0.0003).